The Feinstein Institute for Medical Research

Empowering Imagination. Pioneering Discovery.
Print | Font Size ( + ) ( - ) | Bookmark | Email

Ping Wang, MD

Vice Chairman for ResearchDepartment of Surgery, North Shore University Hospital
and Long Island Jewish Medical Center

Head, Center for Translational Research, The Feinstein Institute for Medical Research

Investigator and Director of Laboratory of Surgical Research, The Feinstein Institute for Medical Research

Professor of Surgery and Molecular Medicine, Hofstra North Shore-LIJ School of Medicine

Phone: (516) 562-3411
Email: pwang@nshs.edu

About the Investigator

Ping Wang, MD, is vice chairman for research in the department of surgery at North Shore University Hospital and Long Island Jewish Medical Center. He is also professor of surgery and molecular medicine at Hofstra North Shore-LIJ School of Medicine and an investigator and head of the Center for Translational Research in The Feinstein Institute for Medical Research.

Prior to joining the department of surgery at North Shore University Hospital and Long Island Jewish Medical Center, Dr. Wang held positions of associate professor in the department of surgery at Brown University School of Medicine and professor of surgery (with tenure), professor of pathology, physiology and biophysics at University of Alabama at Birmingham (UAB).

In 2002, Dr. Wang became professor of surgery at Albert Einstein College of Medicine and chief of the division of surgical research at North Shore University Hospital and Long Island Jewish Medical Center. Dr. Wang is a member of various societies, including American Physiological Society, Shock Society, Society of Critical Care Medicine, Surgical Infection Society, Society for Leukocyte Biology, Association for Academic Surgery, American Heart Association, American Association for the Advancement of Science and NY Academy of Science.

Dr. Wang is also the editor-in-chief of International Journal of Clinical and Experimental Medicine. He serves as the editorial board member for: Shock, Int J Mol Med, Digestive Surgery, Frontiers of Medicine, International Journal of Clinical and Experimental Pathology, Experimental and Therapeutic Medicine, American Journal of Translational Research, Hepatic Medicine, and International Journal of Burns and Trauma. He served as guest reviewer for: Am J Physiol, Am J Respir Crit Care Med, Arch Surg, Atherosclerosis, Biochim Biophys Acta, Cardiovasc Res, Crit Care Med, Free Radical Bio Med, Horm Metab Res, J Surg Res, Mol Cell Biochem, Nat Protoc, Hypertension, Peptides, Surg Infec, Life Sciences, J Hepatol, Physiol Genomics, Exp Biol Med, Front Biosci, J Leukoc Biol, J Endocrinol, Infect Immun, J Immunol, Infect Immun, J Pharmacol Exp Ther, Nat Protoc. Reviewer for: US Army Hemorrhage Control Research Program Review. Dr. Wang is co-founder of TheraSource LLC. He also was a member of various NIH Study Sections and VA Surgery Study Section.

In 1995, Dr. Wang received the NIH FIRST Award and has continually been funded by the NIH. The Laboratory of Surgical Research was originated in 2002 in the Department of Surgery. Since then, the lab has grown extensively and currently has about 20 team members ranging from associate investigator/professor to PhD students.

In addition, Dr. Wang is a mentor for junior faculty, postdoctoral fellows and graduate students within his lab and for other individuals at The Feinstein Institute for Medical Research, as well as other institutions. A number of the scientists and postdoctoral fellows from the lab received awards such as the New Investigator Award, Annual Scientific Award and travel awards. Dr. Wang and colleagues publish more than 340 articles in peer-reviewed journals.

Research Focus

Sepsis often occurs in many critical illnesses. Despite advances in the management of sepsis, a large number of patients die of the ensuing septic shock and multiple organ failure. Similarly, a large number of such patients die of circulatory collapse due to blood loss with progressive cell and organ damage. Dr. Wang’s long-term goal is to develop better therapies to prevent progression of these processes. Currently, he is focusing on a number of potential drug candidates and is in the preclinical stage to develop them as therapies for sepsis and other organ injuries, which include hemorrhagic shock, ischemia and reperfusion injury, radiation injury and focal cerebral ischemia (stroke).

Recently Dr. Wang identified a novel inflammatory mediator, cold inducible RNA-binding protein (CIRP) in animal models of hemorrhage and sepsis as well as in the blood of individuals admitted to the surgical intensive care unit with hemorrhagic shock. In rodents, blockade of CIRP using antisera to CIRP attenuated inflammatory cytokine release and mortality after hemorrhage and sepsis. The activity of extracellular CIRP is mediated through the Toll-like receptor 4 interactions and CIRP is confirmed as a damage associated molecular pattern molecule that promotes inflammation in shock and sepsis. Studies are underway to generate inhibitors of CIRP in an effort to develop them as therapy for hemorrhagic shock and other injury conditions. We are also currently enrolling patients from our surgical intensive care unit to correlate the blood levels of CIRP to clinical parameters of hemorrhagic shock and patient outcome.

After the discovery that CIRP as a novel mediator of shock and sepsis, we extended our studies to examine its role in neuroinflammation. We demonstrated that CIRP plays an important role in stroke-associated neuroinflammation and brain injury. We also showed that CIRP is an important mediator in alcohol-induced brain inflammation. Studies are ongoing to examine additional functions of CIRP in brain related injuries.

Milk fat globule-EGF Factor 8 (MFG-E8) is a glycoprotein secreted by activated macrophages and immature dendritic cells and promotes the engulfment of apoptotic cells by working as a bridging molecule between those cells and phagocytes. Dr. Wang has shown that MFG-E8 is downregulated in sepsis and that the administration of recombinant MFG-E8 during sepsis provided beneficial effects, including attenuating pro-inflammatory response, increasing apoptotic cell clearance, and improving survival in sepsis. MFG-E8 treatment reduces acute lung injury caused by an intestinal ischemia and reperfusion injury model. Studies are being done to establish the efficacy and optimal dosage of recombinant human MFG-E8 in an attempt to develop this as a therapy for sepsis and other organ injury conditions.  In addition, a novel peptide derived from MFG-E8 has shown to be protective in sepsis and preclinical studies are now ongoing to determine the efficacy of this peptide in sepsis.  Currently we are conducting preclinical studies to examine the efficacy of recombinant human MFG-E8 as a treatment for inflammatory bowel disease.

Adrenomedullin (AM) is a potent vasoactive peptide. While AM is increased in sepsis and other injury conditions, AM is hyporesponsive due to the lack of its binding protein, AMBP-1. Dr. Wang has shown that treatment with AM/AMBP-1 is beneficial in sepsis, gut and renal and hepatic ischemia and reperfusion injuries, and cerebral ischemic rodent models. Pharmacokinetic and pharmacotoxicity studies are currently underway to develop AM/AMBP-1 as therapy for sepsis and other organ injuries. We are extending these studies in non-rodent species to file an investigational drug (IND) application to the FDA for initiating clinical trials in various injury conditions.

Ghrelin, a novel stomach derived peptide, is reduced in sepsis and other injury conditions. The downregulation of ghrelin activates sympathostimulatory nuclei in the brain, increasing NE release from the sympathetic nerve fibers in the gut, resulting in upregulation of proinflammatory cytokines and subsequent injuries to the liver and other organs (the brain-gut-liver axis paradigm). He has also shown that treatment with ghrelin downregulates organ injury in renal ischemia reperfusion injury, radiation combined injury, and focal cerebral ischemia.  Dr. Wang’s results showed that ghrelin acts via the vagus nerve to downregulate proinflammatory responses in sepsis, renal ischemia reperfusion injury, radiation combined injury and focal cerebral ischemia.  Preclinical studies are ongoing to develop ghrelin as a radiation mitigator for patients suffering from nuclear disaster related complications.

Lab Members







Monowar Aziz, PhD
Research Scientist
Research: Immunology and Inflammation
Email: maziz1@nshs.edu

Max Brenner, MD, PhD
Assistant Investigator
Research: Chronic Inflammatory Diseases
Email: mbrenner@nshs.edu

Wayne Chaung, PhD
Assistant Investigator 
Research: Inflammatory Mediators
Email: wchaung@nshs.edu

Andrew J. Godwin, MD
Surgical Resident (Research)
Research: Hepatic Ischemia Reperfusion Injury
Email: agodwin@nshs.edu

Yohei Hirano, MD
Post Doctoral Research Fellow
Research: Pathophysiology of Inflammation
Email: yhirano@nshs.edu

Adam Khader, MD
Elmezzi Scholar, PhD Candidate
Research: Emerging Metabolism and Ischemic Injury
Email: akhader@nshs.edu

Maria Ma, MD
Research Scientist
Research: Drug Discovery and Development
Email: gma@nshs.edu

Nikhil Mulchandani, MD
Surgical Resident (Research)
Research: Central Nervous System and Sepsis
Email: nmulchandani@nshs.edu

Mahendar Ochani, MD
Assistant Investigator
Research: Animal Models of Human Diseases
Email: mochani@nshs.edu

Jose M. Prince, MD
Assistant Professor
Research: Necrotizing Colitis and Sepsis
Email: jprince@nshs.edu

Xiaoling Qiang, MD, PhD
Research Scientist
Research: Inflammatory Mediators

Madeline Ann Quinn
Administrative Manager
Research: Laboratory Manager
Email: maquinn@nshs.edu

Archna Sharma, PhD
Research Scientist
Research: Cellular Immunity and Inflammation
Email: asharma11@nshs.edu

Asha Varghese, PhD
Associate Investigator
Research: Alcohol and Neurosuppression
Email: avarghes@nshs.edu

Wendy Wang, MD
Research Associate
Research: Inflammation and Drug Development
Email: zwang@nshs.edu

Weng-Lang Yang, PhD
Associate Investigator/Associate Professor
Research: Inflammation and Signaling Pathways
Email: wlyang@nshs.edu

Tim Yen, MS
Research Associate
Research: In vivo Studies
Email: hyen@nshs.edu

Fangming Zhang, MD, PhD
Research Scientist
Research: Inflammatory Diseases
Email: fzhang1@nshs.edu

Mian Zhou, MD
Senior Research Scientist
Research: Sepsis, Hemorrhage, Ischemia/Reperfusion Injury
Email: mzhou@nshs.edu


Changwei Medical College, China
Degree: MD
Field of Study: Medicine

Third Medical University, China
Degree: MS
Field of Study: Surgery

University of Washington, Seattle, WA
Degree: Postdoctoral
Field of Study: Pharmacology

Brown University, Providence, RI
Degree: MA
Field of Study: Honorary MA

Honors and Awards

1995-2000 NIH FIRST Award (R29)
1996-2001 NIH Independent Scientist Award (K02)
1998 Master of Arts Degree ad eundem, Brown University
2002 Annual Scientific Award, Society of Critical Care Medicine
2011 Annual Scientific Award, Society of Critical Care Medicine

  1. Cui T, Miksa M, Wu R, Komura H, Zhou M, Dong W, Wang Z, Higuchi S, Chaung W, Blau S, Marini CP, Ravikumar TS, Wang P: “Milk fat globule epidermal growth factor 8 attenuates acute lung injury in mice after intestinal ischemia and reperfusion.” Am J Respir Crit Care Med 181:238-246, 2010 (featured on the cover).
  2. Jacob A, Shah KG, Wu R, Wang P:  “Ghrelin as a novel therapy for radiation combined injury.”  Mol Med 16:137-143, 2010.
  3. Matsuda A, Wu R, Jacob A, Komura H, Zhou M, Wang Z, Aziz MM, Wang P: “Protective effect of milk fat globule epidermal growth factor-factor VIII after renal ischemia-reperfusion injury in mice” (Feature Article).  Crit Care Med 39-2039-2047, 2011.
  4. Chaung WW, Wu R, Ji Y, Wang Z, Dong W, Cheyuo C, Qi L, Qiang X, Wang H, Wang P:  “Peripheral administration of human adrenomedullin and its binding protein attenuates stroke-induced apoptosis and brain injury in rats.”  Mol Med 17:1075-1083, 2011.  (PMC3188865)
  5. Aziz MM, Jacob A, Matsuda A, Wu R, Zhou M, Dong W, Yang W-L, Wang P:  “Pre-treatment of recombinant mouse MFG-E8 downregulates LPS-induced TNF-a production in macrophages via STAT3-mediated SOCS3 activation.”  PLoS ONE 6:e27685, 2011 (12 pages).  
  6. Matsuda A,Jacob A, Wu R, Zhou M, Nicastro JM, Coppa GF, Wang P:  “Milk fat globule-EGF factor VIII in sepsis and ischemia-reperfusion injury.”  Mol Med 17:126-133, 2011.
  7. Cheyuo C, Jacob A, Wu R, Zhou M, Coppa G, Wang P:  “The parasympathetic nervous system in the quest for stroke therapeutics.”  J Cerebr Blood F Met 31:1187-1195, 2011.
  8. Aziz MM, Jacob A, Matsuda A, Wang P:  “Milk fat globulin-EGF factor-8 expression, functions and plausible signal transduction in resolving inflammation.”  Apoptosis 16:1077-1086, 2011.
  9. Shah KG, Wu R, Jacob A, Molmenti EP, Nicastro J, Coppa GF, Wang P:  “Recombinant human milk fat globule-EGF factor 8 produces dose-dependent benefits in sepsis.”  Intensive Care Med 38:128-136, 2012.
  10. Cheyuo C, Jacob A, Wu R, Zhou M, Qi L, Dong W, Ji Y, Chaung WW, Wang H, Nicastro J, Coppa GF, Wang P: “Recombinant human MFG-E8 attenuates cerebral ischemic injury: its role in anti-inflammation and anti-apoptosis.” Neuropharm 62:890-900, 2012.
  11. Aziz MM, Matsuda A, Yang W-L, Jacob A, Wang P:  “Milk fat globule-epidermal growth factor-factor 8 attenuates neutrophil infiltration in acute lung injury via modulation of CXCR2.”   J Immunol 189:393-402, 2012.
  12. Cheyuo C, Yang W-L, Wang P:  “The critical role of adrenomedullin and its binding protein, AMBP-1, in neuroprotection.”  Biol Chem 393:429-439, 2012.
  13. Ajakaiye MA, Jacob A, Wu R, Yang W-L, Nicastro J, Coppa GF, Wang P:  Recombinant human MFG-E8 attenuates intestinal injury and mortality in severe whole body irradiation in rats.  PLoS ONE 7:e46540, 2012 (9 pages).
  14. Cheyuo C, Jacob A, Wang P:  “Ghrelin-mediated sympathoinhibition and suppression of inflammation in sepsis.”  Am J Physiol Endocrinol Metab 302:E265-E272, 2012
  15. Aziz M, Jacob A, Yang W-L, Matsuda A, Wang P:  “Current trends in inflammatory and immunomodulatory mediators in sepsis.”  J Leukoc Biol 93:329-342, 2013.
  16. Kuncewitch K, Yang W-L, Molmenti EP, Nicastro J, Coppa GF, Wang P:  “Wnt agonist attenuates liver injury and improves survival after hepatic ischemia/reperfusion.”  Shock 39:3-10, 2013 (featured in the cover).
  17. Matsuo S, Yang W-L, Aziz M, Jacob A, Wang P:  “Cyclic arginine-glycine-aspartate attenuates acute lung injury in mice after intestinal ischemia-reperfusion.”  Crit Care 17:R19, 2013 (12 pages).
  18. Zhou M, Wang CW, Yang W-L, Wang P:  “Microglial CD14 activated by iNOS contributes to neuroinflammation in cerebral ischemia.” Brain Res 1506:105-114, 2013.
  19. Giangola MD, Yang W-L, Rajayer SR, Nicastro J, Coppa GF, Wang P:  “Growth arrest-specific protein 6 (Gas6) attenuates neutrophil migration and acute lung injury in sepsis.” Shock 40:485-491, 2013.
  20. Qiang X*, Yang W-L*, Wu R, Zhou M, Jacob A, Dong W, Kuncewitch M, Ji Y, Yang H, Wang H, Fujita J, Nicastro J, Coppa GF, Tracey KJ, Wang P:  “Cold-inducible RNA-binding protein (CIRP) triggers inflammatory responses in hemorrhagic shock and sepsis.”  Nat Med 19:1489-1495, 2013.  *equal contributors
  21. Matsuda A, Yang W-L, Jacob A, Aziz M, Matsuo S, Matstani T, Uchida E, Wang P:  “FK866, a visfatin inhibitor, protects against acutel lung injury after intestinal ischemia-reperfusion in mice via NF-kB pathway.”  Ann Surg 2013 Oct 28. [Epub ahead of print]
  22. Rajayer SR,Jacob A, Yang W-L, Zhou M, Chaung W, Wang P:  “Cold-inducible RNA-binding protein is an important mediator of acute alcohol-induced brain inflammation.”  PLoS ONE 8:e79430, 2013 (7 pages).
  23. Matsuo S, Yang W-L, Aziz M, Kameoka S, Wang P:  “Fatty acid synthase inhibitor C75 ameliorates experimental colitis.” Mol Med  20:1-9, 2014.
  24. Aziz M, Yang W-L, Matsuo S, Sharma A, Zhou M, Wang P:  “Upregulation of GRAIL is associated with impaired CD4 T-cell proliferation in sepsis.”  J Immunol 192:2305-2314, 2014.

View more recent publications at PubMed (since 2003)